Overview Dividends

(PGNY) Progyny - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74340E1038

Fertility Benefits, Pharmacy Solution, Adoption Assistance

Health Care Services
Market Cap in USD: 2,219m

IPO / Inception: 2019-10-25
Return 12m vs S&P 500: 30.2%

EPS (Earnings per Share)

EPS CAGR: 34.04%
EPS Trend: 80.7%

Last SUE: 2.62
Qual. Beats: 2

Revenue

Rev. CAGR: 27.08%
Rev. Trend: 88.6%

Last SUE: 1.14
Qual. Beats: 4

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	45.2%
Value at Risk 5%th	66.3%
Relative Tail Risk	-10.71%

Reward TTM
Sharpe Ratio	1.02
Alpha	37.32
CAGR/Max DD	-0.06

Character TTM
Hurst Exponent	0.512
Beta	0.574
Beta Downside	0.290

Drawdowns 3y
Max DD	68.14%
Mean DD	32.88%
Median DD	36.57%

Description: PGNY Progyny November 11, 2025

Progyny, Inc. (NASDAQ:PGNY) is a U.S. benefits-management firm that specializes in fertility, family-building, and women’s health solutions for employers. Its product suite includes a differentiated fertility benefits design (e.g., smart-cycle treatment bundles), concierge-style member support, a curated network of fertility specialists, an integrated pharmacy offering (Progyny Rx) with medication access and care-management, and a reimbursement-based assistance program covering adoption, surrogacy, doula services, and travel costs.

Key operational metrics (FY 2023) show revenue of approximately $1.5 billion, up roughly 30% year-over-year, driven by a 45% increase in covered lives to about 8 million members. The fertility-benefits market is expanding at a 12% CAGR, fueled by rising infertility rates (≈15% of U.S. couples) and growing employer demand for comprehensive family-building perks. A sector-wide driver is the shift toward value-based care, which aligns with Progyny’s bundled-payment model and its emphasis on outcome-based care coordination.

For a deeper, data-rich assessment of Progyny’s valuation dynamics, you may find ValueRay’s analytical platform useful as a next step in your research.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (56.6m TTM) > 0 and > 6% of Revenue (6% = 76.1m TTM)

FCFTA 0.24 (>2.0%) and ΔFCFTA -0.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 32.44% (prev 29.67%; Δ 2.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.26 (>3.0%) and CFO 205.1m > Net Income 56.6m (YES >=105%, WARN >=100%)

Net Debt (-109.3m) to EBITDA (95.4m) ratio: -1.14 <= 3.0 (WARN <= 3.5)

Current Ratio 2.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (90.2m) change vs 12m ago -3.83% (target <= -2.0% for YES)

Gross Margin 22.94% (prev 21.68%; Δ 1.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 174.4% (prev 172.5%; Δ 1.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -21.47 (EBITDA TTM 95.4m / Interest Expense TTM -4.24m) >= 6 (WARN >= 3)

Altman Z'' 5.87

(A) 0.52 = (Total Current Assets 622.0m - Total Current Liabilities 210.5m) / Total Assets 795.2m

(B) 0.24 = Retained Earnings (Balance) 190.3m / Total Assets 795.2m

(D) 0.81 = Book Value of Equity 190.8m / Total Liabilities 235.2m

Total Rating: 5.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.22

1. Piotroski 5.50pt

2. FCF Yield 10.03%

3. FCF Margin 15.01%

4. Debt/Equity 0.04

5. Debt/Ebitda -1.14

6. ROIC - WACC (= 2.66)%

7. RoE 11.52%

8. Rev. Trend 88.59%

9. EPS Trend 80.71%

What is the price of PGNY shares?

As of January 07, 2026, the stock is trading at USD 26.67 with a total of 1,621,794 shares traded.
Over the past week, the price has changed by +3.21%, over one month by +7.98%, over three months by +32.10% and over the past year by +53.01%.

Is PGNY a buy, sell or hold?

Progyny has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold PGNY.

Strong Buy: 4
Buy: 0
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PGNY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	29.4	10.2%
Analysts Target Price	29.4	10.2%
ValueRay Target Price	29.5	10.5%

PGNY Fundamental Data Overview January 05, 2026

Market Cap USD = 2.22b (2.22b USD * 1.0 USD.USD)
P/E Trailing = 41.5161
P/E Forward = 12.8041
P/S = 1.7491
P/B = 3.9626
Beta = 0.972
Revenue TTM = 1.27b USD
EBIT TTM = 91.0m USD
EBITDA TTM = 95.4m USD
Long Term Debt = 24.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.86m USD (from shortTermDebt, last fiscal year)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.90b USD (2.22b + Debt 24.7m - CCE 345.2m)
Interest Coverage Ratio = -21.47 (Ebit TTM 91.0m / Interest Expense TTM -4.24m)
FCF Yield = 10.03% (FCF TTM 190.4m / Enterprise Value 1.90b)
FCF Margin = 15.01% (FCF TTM 190.4m / Revenue TTM 1.27b)
Net Margin = 4.46% (Net Income TTM 56.6m / Revenue TTM 1.27b)
Gross Margin = 22.94% ((Revenue TTM 1.27b - Cost of Revenue TTM 977.7m) / Revenue TTM)
Gross Margin QoQ = 23.24% (prev 23.72%)
Tobins Q-Ratio = 2.39 (Enterprise Value 1.90b / Total Assets 795.2m)
Interest Expense / Debt = 2.85% (Interest Expense 706.0k / Debt 24.7m)
Taxrate = 42.15% (10.1m / 24.0m)
NOPAT = 52.6m (EBIT 91.0m * (1 - 42.15%))
Current Ratio = 2.96 (Total Current Assets 622.0m / Total Current Liabilities 210.5m)
Debt / Equity = 0.04 (Debt 24.7m / totalStockholderEquity, last quarter 560.0m)
Debt / EBITDA = -1.14 (Net Debt -109.3m / EBITDA 95.4m)
Debt / FCF = -0.57 (Net Debt -109.3m / FCF TTM 190.4m)
Total Stockholder Equity = 491.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.11% (Net Income 56.6m / Total Assets 795.2m)
RoE = 11.52% (Net Income TTM 56.6m / Total Stockholder Equity 491.1m)
RoCE = 17.64% (EBIT 91.0m / Capital Employed (Equity 491.1m + L.T.Debt 24.7m))
RoIC = 10.72% (NOPAT 52.6m / Invested Capital 491.1m)
WACC = 8.06% (E(2.22b)/V(2.24b) * Re(8.13%) + D(24.7m)/V(2.24b) * Rd(2.85%) * (1-Tc(0.42)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.37%
[DCF Debug] Terminal Value 81.16% ; FCFE base≈178.4m ; Y1≈220.1m ; Y5≈375.5m
Fair Price DCF = 72.88 (DCF Value 6.28b / Shares Outstanding 86.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 80.71 | EPS CAGR: 34.04% | SUE: 2.62 | # QB: 2
Revenue Correlation: 88.59 | Revenue CAGR: 27.08% | SUE: 1.14 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.49 | Chg30d=+0.006 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=1.96 | Chg30d=+0.015 | Revisions Net=+5 | Growth EPS=+8.5% | Growth Revenue=+9.5%

Additional Sources for PGNY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle